4098-06-0 Usage
Description
3,4,6-Tri-O-acetyl-D-galactal is a pale yellow oil that serves as an essential building block for the synthesis of oligosaccharides, which are complex carbohydrates consisting of a chain of monosaccharide units. Its chemical structure allows it to be used in both solution and solid-phase synthesis methods, making it a versatile compound in the field of carbohydrate chemistry.
Uses
Used in Pharmaceutical Industry:
3,4,6-Tri-O-acetyl-D-galactal is used as a key intermediate for the synthesis of various pharmaceutical compounds, particularly those involving oligosaccharides. Its role in the creation of these complex carbohydrates is crucial for the development of new drugs and therapies.
Used in Chemical Research:
In the field of chemical research, 3,4,6-Tri-O-acetyl-D-galactal is used as a starting material for the synthesis of a wide range of complex organic compounds. Its unique structure allows researchers to explore new reactions and develop novel chemical pathways.
Used in Material Science:
3,4,6-Tri-O-acetyl-D-galactal is also utilized in material science for the development of new materials with specific properties. Its ability to form oligosaccharides can be harnessed to create materials with unique characteristics, such as improved biocompatibility or enhanced mechanical properties.
Used in Food Industry:
In the food industry, 3,4,6-Tri-O-acetyl-D-galactal can be used as a component in the development of new food additives or ingredients. Its role in the synthesis of oligosaccharides can lead to the creation of novel compounds with specific flavors, textures, or nutritional benefits.
Overall, 3,4,6-Tri-O-acetyl-D-galactal is a versatile compound with a wide range of applications across various industries, including pharmaceuticals, chemical research, material science, and the food industry. Its importance as a building block for the synthesis of oligosaccharides makes it a valuable asset in the development of new products and technologies.
Check Digit Verification of cas no
The CAS Registry Mumber 4098-06-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,0,9 and 8 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 4098-06:
(6*4)+(5*0)+(4*9)+(3*8)+(2*0)+(1*6)=90
90 % 10 = 0
So 4098-06-0 is a valid CAS Registry Number.
InChI:InChI=1/C12H16O7/c1-7(13)17-6-11-12(19-9(3)15)10(4-5-16-11)18-8(2)14/h4-5,10-12H,6H2,1-3H3/t10-,11-,12-/m1/s1
4098-06-0Relevant articles and documents
Diastereoselective Synthesis of Thioglycosides via Pd-Catalyzed Allylic Rearrangement
Jiang, Xuefeng,Li, Jiagen,Wang, Ming
supporting information, p. 9053 - 9057 (2021/11/30)
Stereoselective glycosylation is challenging in carbohydrate chemistry. Herein, stereoselective thioglycosylation of glycals via palladium-catalyzed allylic rearrangement yields various substituents on α-isomer thioglycosides. Two comprehensive series of aryl and benzyl thioglycosides were obtained via a combination of thiosulfates with glycals derived from glucose, arabinose, galactose, and rhamnose. Furthermore, diosgenyl α-l-rhamnoside and isoquercitrin achieved selectivity via stereospecific [2,3]-sigma rearrangements of α-sulfoxide-rhamnoside and α-sulfoxide-glucoside, respectively.
Efficient and reproducible synthesis of an Fmoc-protected Tn antigen
Chapa-Villarreal, Fabiola A.,Chiaramonte, Jonathan,Piazza, Sabrina M.,Reynolds, Michael R.,Trant, John F.,Xu, Peihan
, p. 19224 - 19227 (2021/11/09)
This concise total synthesis of the Thomsen-Nouveau (Tn) glycoconjugate was accomplished using a palladium-catalyzed coupling between the glycosyl donor and Fmoc-protected serine acceptor. This is, to the best of our knowledge, the shortest synthesis reported from galactose for preparing this essential building block for large-scale solid phase peptide synthesis.
ENGINEERED ANTIBODIES AS MOLECULAR DEGRADERS THROUGH CELLULAR RECEPTORS
-
Page/Page column 3; 77, (2021/04/17)
The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In certain embodiments, the circulating protein mediates a disease and/or disorder in a subject, and treatment or management of the disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein in the subject. Thus, in certain embodiments, administration of a compound of the disclosure to the subject removes or reduces the circulation concentration of the circulating protein, thus treating, ameliorating, or preventing the disease and/or disorder.
